Lung Therapeutics Announces Appointment of Sharon Morriss, PhD, as Senior Vice President of Clinical Development

Key leadership appointment of Dr. Morriss enhances the company’s research and development efforts of new therapeutic applications for the treatment of fibrotic diseases and conditions

AUSTIN, Texas--(BUSINESS WIRE)-- Lung Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for orphan, pulmonary diseases and conditions, today announced the appointment of Sharon Morriss, PhD, as Senior Vice President of Clinical Development. In this critical role, she will be responsible for guiding Lung Therapeutics’ clinical programs and will serve as a key member of the company’s executive leadership team. Dr. Morriss joins the company with more than fifteen years of experience leading biotechnology clinical development teams from pre-clinical to commercialization.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210713005392/en/

Sharon Morriss, PhD, Lung Therapeutics Senior Vice President of Clinical Development (Photo: Business Wire)

Brian Windsor, President & CEO, Lung Therapeutics, Inc., said, “Dr. Morriss has a track record of developing successful drug programs and building clinical teams for all phases of development. Her deep clinical knowledge and experience will be instrumental as we continue to grow Lung Therapeutics and advance our pipeline. We are excited to have Dr. Morriss join us.”

“I am thrilled to join Lung Therapeutics and work alongside this driven, entrepreneurial team. The early clinical and pre-clinical data generated with drug candidates LTI-01 and LTI-03 are compelling,” stated Dr. Morriss. “It is an honor to lead the clinical development team in expansion of effective treatment options for patients with serious unmet medical needs.”

Before joining Lung Therapeutics, Dr. Morriss served as Senior Vice President, Clinical Development Operations, at Apellis Pharmaceuticals, where she played a key leadership role in the advancement of the company’s rare disease and ophthalmology clinical portfolio. This led to the FDA approval of EMPAVELI™ (pegcetacoplan), a targeted C3 therapy for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). Dr. Morriss built and led the global clinical development operations team to advance the diverse clinical platform through to registrational clinical studies in hematology, nephrology, neurology, and ophthalmology. Dr. Morriss also chaired the Joint Development Committee for Apellis’ global co-development alliance for systemic pegcetacoplan with Swedish Orphan Biovitrum (Sobi™).

Dr. Morriss holds a Bachelor of Science degree (Hons) in Zoology (Parasitology) from the University of Aberdeen in Scotland, and a PhD in Molecular Biology/Biochemistry from the University of Stirling, Scotland.

About Lung Therapeutics Inc.

Headquartered in Austin, Texas, Lung Therapeutics, Inc. is a clinical stage biopharmaceutical company formed to leverage leading research in orphan, pulmonary indications for which there are unmet medical needs. The company is developing a proprietary pipeline of novel therapeutics with the potential to greatly improve outcomes over currently available treatments. The company’s lead drug LTI-01 has received Orphan Drug Designation in the US and EU and Fast Track Designation in the US. LTI-01 is currently in a Phase 2, randomized, placebo-controlled, double-blind, dose-ranging study evaluating LTI-01 in patients with infected, non-draining loculated pleural effusions. The company’s second product candidate, LTI-03, is in development for idiopathic pulmonary fibrosis. For more information, visit Lung Therapeutics, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210713005392/en/